HealthDay News — Baricitinib demonstrates sustained long-term efficacy in patients with moderate-to-severe atopic dermatitis, according to a study published online May 12 in JAMA Dermatology.
Jonathan I. Silverberg, MD, from the George Washington University School of Medicine in Washington, DC, and colleagues evaluated the long-term (68 weeks) efficacy of baricitinib in adults with moderate-to-severe atopic dermatitis who were treatment responders or partial responders in phase 3 monotherapy studies.
The researchers found that of the responder/partial responder population treated with 4 mg baricitinib (70 patients; mean age, 36.7 years; 60% men), 45.7% achieved validated Investigator Global Assessment for Atopic Dermatitis scores of 0 or 1 (vIGA-AD [0,1]) at week 16; the proportion was 47.1% at week 68. Seventy percent of participants achieved improvement of 75% or greater in the Eczema Area and Severity Index (EASI75) at week 16 vs 55.7% at week 68. Among the responder/partial responder population treated with 2 mg baricitinib (54 patients; mean age, 32.8 years; 51.9% men), 46.3% achieved vIGA-AD (0,1) at week 16 vs 59.3% at week 68. At week 16, improvement in the EASI75 score was 74.1% compared with 81.5% at week 68.
“Overall, these findings provide support that baricitinib may be a longer-term treatment option for patients with moderate-to-severe atopic dermatitis,” the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Eli Lilly and Company, which manufactures baricitinib and funded the study.